Literature DB >> 9271408

Functional differences between Stat3alpha and Stat3beta.

T S Schaefer1, L K Sanders, O K Park, D Nathans.   

Abstract

Stat3beta is a short form of Stat3 that differs from the longer form (Stat3alpha) by the replacement of the C-terminal 55 amino acid residues of Stat3alpha by 7 residues specific to Stat3beta. In COS cells transfected with Stat3 expression plasmids, both Stat3alpha and Stat3beta were activated for DNA binding and transcription by the same set of growth factors and cytokines and both, when activated, formed homodimers and heterodimers with Stat1. Only Stat3beta was active in the absence of added cytokine or growth factor. Activation of each form, including constitutive activation of Stat3beta, was correlated with the phosphorylation of tyrosine 705. Activated Stat3beta in transfected COS cells was more stable and had greater DNA-binding activity than activated Stat3alpha. However, relative to DNA-binding activity, Stat3alpha showed greater transcriptional activity than Stat3beta. A mutant of Stat3alpha lacking its highly acidic C-terminal 48 amino acids had properties indistinguishable from Stat3beta. We conclude that Stat3alpha and Stat3beta have significantly different properties due to the presence or absence of the acidic C-terminal tail of Stat3alpha rather than the C-terminal sequence peculiar to Stat3beta. In addition to its effect on transcription, we speculate that the acidic tail may destabilize the active dimeric form of Stat3alpha, resulting in lower DNA-binding activity of the Y705-phosphorylated form compared to Stat3beta and in more rapid dephosphorylation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9271408      PMCID: PMC232381          DOI: 10.1128/MCB.17.9.5307

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  39 in total

1.  In vitro activation of Stat3 by epidermal growth factor receptor kinase.

Authors:  O K Park; T S Schaefer; D Nathans
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

2.  Identification of the promoter sequences involved in the interleukin-6 dependent expression of the rat alpha 2-macroglobulin gene.

Authors:  D Kunz; R Zimmermann; M Heisig; P C Heinrich
Journal:  Nucleic Acids Res       Date:  1989-02-11       Impact factor: 16.971

3.  Functional interactions between Stat5 and the glucocorticoid receptor.

Authors:  E Stöcklin; M Wissler; F Gouilleux; B Groner
Journal:  Nature       Date:  1996-10-24       Impact factor: 49.962

4.  Naturally occurring dominant negative variants of Stat5.

Authors:  D Wang; D Stravopodis; S Teglund; J Kitazawa; J N Ihle
Journal:  Mol Cell Biol       Date:  1996-11       Impact factor: 4.272

5.  The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA-mediated transfection.

Authors:  C M Gorman; G T Merlino; M C Willingham; I Pastan; B H Howard
Journal:  Proc Natl Acad Sci U S A       Date:  1982-11       Impact factor: 11.205

6.  Assay of transforming activity of tumor virus DNA.

Authors:  A J van der Eb; F L Graham
Journal:  Methods Enzymol       Date:  1980       Impact factor: 1.600

7.  Differences in sequences encoding the carboxyl-terminal domain of the epidermal growth factor receptor correlate with differences in the disease potential of viral erbB genes.

Authors:  D C Gamett; S E Tracy; H L Robinson
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

8.  Deletion of the carboxyl-terminal transactivation domain of MGF-Stat5 results in sustained DNA binding and a dominant negative phenotype.

Authors:  R Moriggl; V Gouilleux-Gruart; R Jähne; S Berchtold; C Gartmann; X Liu; L Hennighausen; A Sotiropoulos; B Groner; F Gouilleux
Journal:  Mol Cell Biol       Date:  1996-10       Impact factor: 4.272

9.  Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences.

Authors:  J Downward; Y Yarden; E Mayes; G Scrace; N Totty; P Stockwell; A Ullrich; J Schlessinger; M D Waterfield
Journal:  Nature       Date:  1984 Feb 9-15       Impact factor: 49.962

10.  Granulocyte colony-stimulating factor activation of Stat3 alpha and Stat3 beta in immature normal and leukemic human myeloid cells.

Authors:  A Chakraborty; S M White; T S Schaefer; E D Ball; K F Dyer; D J Tweardy
Journal:  Blood       Date:  1996-10-01       Impact factor: 22.113

View more
  28 in total

Review 1.  Role of the JAK/STAT signal transduction pathway in the regulation of gene expression in CNS.

Authors:  P Dell'Albani; R Santangelo; L Torrisi; V G Nicoletti; A M Giuffrida Stella
Journal:  Neurochem Res       Date:  2003-01       Impact factor: 3.996

2.  Negative regulation of STAT92E by an N-terminally truncated STAT protein derived from an alternative promoter site.

Authors:  Melissa A Henriksen; Aurel Betz; Marc V Fuccillo; James E Darnell
Journal:  Genes Dev       Date:  2002-09-15       Impact factor: 11.361

3.  Antitumorigenic potential of STAT3 alternative splicing modulation.

Authors:  Francesca Zammarchi; Elisa de Stanchina; Eirini Bournazou; Teerawit Supakorndej; Kathryn Martires; Elyn Riedel; Adriana D Corben; Jacqueline F Bromberg; Luca Cartegni
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-17       Impact factor: 11.205

4.  Receptor/gene/protein-mediated signaling connects methylprednisolone exposure to metabolic and immune-related pharmacodynamic actions in liver.

Authors:  Vivaswath S Ayyar; Siddharth Sukumaran; Debra C DuBois; Richard R Almon; Jun Qu; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-04-27       Impact factor: 2.745

5.  Cytosolic DNA Promotes Signal Transducer and Activator of Transcription 3 (STAT3) Phosphorylation by TANK-binding Kinase 1 (TBK1) to Restrain STAT3 Activity.

Authors:  Hung-Ching Hsia; Jessica E Hutti; Albert S Baldwin
Journal:  J Biol Chem       Date:  2017-02-10       Impact factor: 5.157

6.  Antisense Modulation of RNA Processing as a Therapeutic Approach in Cancer Therapy.

Authors:  Lee Spraggon; Luca Cartegni
Journal:  Drug Discov Today Ther Strateg       Date:  2013

7.  Signal transducer and activation of transcription (STAT) 4beta, a shorter isoform of interleukin-12-induced STAT4, is preferentially activated by estrogen.

Authors:  Ebru Karpuzoglu; Rebecca A Phillips; Rujuan Dai; Carmine Graniello; Robert M Gogal; S Ansar Ahmed
Journal:  Endocrinology       Date:  2008-11-06       Impact factor: 4.736

8.  Stat3β mitigates development of atherosclerosis in apolipoprotein E-deficient mice.

Authors:  Jihyun Lee; William M Baldwin; Chih-Yuan Lee; Stephen Desiderio
Journal:  J Mol Med (Berl)       Date:  2013-04-26       Impact factor: 4.599

9.  Distinct requirements for the naturally occurring splice forms Stat4alpha and Stat4beta in IL-12 responses.

Authors:  Timothy Hoey; Shangming Zhang; Nathan Schmidt; Qing Yu; Shyam Ramchandani; Xiang Xu; Lisa K Naeger; Ya-Lin Sun; Mark H Kaplan
Journal:  EMBO J       Date:  2003-08-15       Impact factor: 11.598

Review 10.  Principles of interleukin (IL)-6-type cytokine signalling and its regulation.

Authors:  Peter C Heinrich; Iris Behrmann; Serge Haan; Heike M Hermanns; Gerhard Müller-Newen; Fred Schaper
Journal:  Biochem J       Date:  2003-08-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.